A batch of a commonly prescribed medication used to treat high blood pressure has been recalled after a packaging mistake led to some boxes containing a stronger dose than intended. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised anyone taking Crescent Pharma’s ramipril 2.5mg capsules to carefully check their packaging.

It comes after a box of the tablets, which are also prescribed for heart failure, kidney disease, or to prevent heart attacks, were found to contain 10mg capsules. Those who have taken a high dose should be aware of side effects such as feeling light-headed, fainting, tiredness or altered kidney function, which could be more serious among vulnerable patients.

The MHRA said Crescent Pharma is recalling one batch of ramipril 2.5mg capsules as a precautionary measure. It follows a complaint from a health professional who found two blister strips of 10mg tablets inside a sealed box labelled 2.5mg. The capsules were made at the same site, the MHRA said, and the error appears to have happened during the packaging process.

Dr Alison Cave, chief safety officer at the MHRA, said: “If you take Crescent Pharma Limited ramipril 2.5mg capsules, check the packaging for batch number GR155023.

“The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication strength on the carton matches the blister strips inside.

“If the 2.5mg carton of Crescent Pharma Limited ramipril contains blister strips that are labelled as ramipril 10mg capsules, do not to take the medicine and contact your dispensing pharmacy.

“If the carton contains blister strips that are correctly labelled as Crescent Pharma Limited ramipril 2.5mg capsules, you do not need to take further action and should continue to take your medicine as usual.

“If you have an affected pack or previously received this batch and you believe you have taken any ramipril 10mg capsules that were included in error and are currently experiencing any side effects, please seek medical advice.”

Dr Cave added that people affected may experience symptoms such as dizziness, fainting, tiredness, or changes in kidney function, with potentially more serious effects in vulnerable patients. He advised that anyone who may have taken a higher dose of ramipril should speak to a healthcare professional, who can assess whether further checks or tests are required.

He also recommended that patients bring the information leaflet and any remaining tablets to their pharmacy or GP practice, and report any suspected side effects through the MHRA Yellow Card scheme.

The MHRA has also advised pharmacies and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.